Weber J - Search Results

1

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.

Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Weber J, et al. Cancer. 2003 Jan 1;97(1):186-200. doi: 10.1002/cncr.11045. Cancer. 2003. PMID: 12491520 Free article. Clinical Trial.

2

Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.

Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, et al. Cole DJ, et al. Among authors: weber j. J Natl Cancer Inst. 1994 Jan 5;86(1):39-45. doi: 10.1093/jnci/86.1.39. J Natl Cancer Inst. 1994. PMID: 8271281 Clinical Trial.

3

Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells.

Kuniyoshi JS, Kuniyoshi CJ, Lim AM, Wang FY, Bade ER, Lau R, Thomas EK, Weber JS. Kuniyoshi JS, et al. Among authors: weber js. Cell Immunol. 1999 Apr 10;193(1):48-58. doi: 10.1006/cimm.1999.1469. Cell Immunol. 1999. PMID: 10202112

4

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.

Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS. Pullarkat V, et al. Among authors: weber js. Cancer Immunol Immunother. 1999 Apr;48(1):9-21. doi: 10.1007/s002620050543. Cancer Immunol Immunother. 1999. PMID: 10235484 Free PMC article. Clinical Trial.

5

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Lee PP, et al. Among authors: weber js. Nat Med. 1999 Jun;5(6):677-85. doi: 10.1038/9525. Nat Med. 1999. PMID: 10371507

6

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Wang F, et al. Among authors: weber j. Clin Cancer Res. 1999 Oct;5(10):2756-65. Clin Cancer Res. 1999. PMID: 10537339 Clinical Trial.

7

A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma.

Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. Weber JS, et al. J Immunother. 1999 Sep;22(5):431-40. doi: 10.1097/00002371-199909000-00007. J Immunother. 1999. PMID: 10546159 Clinical Trial.

8

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. Muderspach L, et al. Among authors: weber j. Clin Cancer Res. 2000 Sep;6(9):3406-16. Clin Cancer Res. 2000. PMID: 10999722 Clinical Trial.

9

Melanoma peptide vaccines: from preclinical background to clinical trials.

Weber J. Weber J. Curr Oncol Rep. 2000 Jan;2(1):38-47. doi: 10.1007/s11912-000-0009-9. Curr Oncol Rep. 2000. PMID: 11122823 Review.

10

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.

Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J. Lau R, et al. Among authors: weber j. J Immunother. 2001 Jan-Feb;24(1):66-78. doi: 10.1097/00002371-200101000-00008. J Immunother. 2001. PMID: 11211150 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,225 results

Search Page

Filters